Braze Inc vs Canopy Growth Corp — how do they compare? Braze Inc trades at $27.58 (market cap $3.18B), while Canopy Growth Corp trades at $1.04 (market cap $421.10M). The key difference: Braze Inc is far larger — about 7.6× Canopy Growth Corp's market cap, and Braze Inc is trading nearer its 52-week high, Canopy Growth Corp nearer its low. Which is the better fit depends on your goals.
| BRZE | CGC | |
|---|---|---|
Market Cap | $3.18B | $421.10M |
Sector | Technology | Health |
52-Week High | $36.19 | $1.92 |
52-Week Low | $15.79 | $0.86 |
Enterprise Value | $2.87B | $378.55M |
Signals from Pluang's Aura AI — not financial advice
Braze (BRZE) trades at $27.71, down 3.62% today, with strong analyst support (96% buy ratings) and a $34.78 consensus price target. The stock shows bullish technical momentum despite recent earnings misses, with revenue growing 30% year-over-year to $593M in 2025. Recent news highlights insider selling and AI-driven sector recovery, while the company maintains robust gross margins of 66.5% but remains unprofitable with a -15.5% net margin.
The outlook remains positive based on accelerating revenue growth and strong institutional backing, though profitability challenges and recent insider selling present near-term risks. With technical indicators showing bullish momentum and the stock trading below analyst targets, BRZE offers growth potential but requires monitoring of execution on path to profitability.
Canopy Growth (CGC) trades at $1.02, up 7.13% with a bullish technical signal. The company reported Q1 fiscal 2027 revenue growth of 13% to C$81.2 million and narrowed its EBITDA loss. While revenue trends show stabilization after declining from $520M in 2022 to $269M in 2025, the company continues to post significant net losses with a -222.36% margin. The balance sheet shows improvement with debt-to-asset ratio declining from 53.61% in 2023 to 33.13% in 2025.
CGC presents a high-risk opportunity with potential catalysts from cannabis rescheduling and European expansion. The stock trades below book value (P/B 0.86) but faces substantial execution risks amid persistent losses. Analyst sentiment is mixed with 33% buy ratings, reflecting optimism about restructuring progress versus concerns about profitability timeline.
Trailing returns across standard periods
Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries.
Read more on BRZE →Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →